Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACOG NASDAQ:CMPX NASDAQ:ESPR NASDAQ:OLMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACOGAlpha Cognition$6.87-1.7%$7.92$3.75▼$11.54$143.60M2.63107,662 shs24,592 shsCMPXCompass Therapeutics$3.97+2.1%$3.61$1.27▼$4.86$548.98M1.481.95 million shs843,015 shsESPREsperion Therapeutics$2.71+1.1%$2.57$0.69▼$3.94$546.40M0.967.98 million shs3.37 million shsOLMAOlema Pharmaceuticals$8.03-0.7%$8.16$2.86▼$13.51$551.13M2.081.56 million shs1.14 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACOGAlpha Cognition0.00%+1.03%-11.01%-31.09%+686,999,900.00%CMPXCompass Therapeutics0.00%-6.81%+13.75%+24.84%+121.79%ESPREsperion Therapeutics0.00%-1.45%+5.86%+79.47%+32.20%OLMAOlema Pharmaceuticals0.00%-14.21%-1.95%+70.49%-32.58%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACOGAlpha Cognition$6.87-1.7%$7.92$3.75▼$11.54$143.60M2.63107,662 shs24,592 shsCMPXCompass Therapeutics$3.97+2.1%$3.61$1.27▼$4.86$548.98M1.481.95 million shs843,015 shsESPREsperion Therapeutics$2.71+1.1%$2.57$0.69▼$3.94$546.40M0.967.98 million shs3.37 million shsOLMAOlema Pharmaceuticals$8.03-0.7%$8.16$2.86▼$13.51$551.13M2.081.56 million shs1.14 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACOGAlpha Cognition0.00%+1.03%-11.01%-31.09%+686,999,900.00%CMPXCompass Therapeutics0.00%-6.81%+13.75%+24.84%+121.79%ESPREsperion Therapeutics0.00%-1.45%+5.86%+79.47%+32.20%OLMAOlema Pharmaceuticals0.00%-14.21%-1.95%+70.49%-32.58%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACOGAlpha Cognition 3.00Buy$18.00162.01% UpsideCMPXCompass Therapeutics 2.91Moderate Buy$13.10229.97% UpsideESPREsperion Therapeutics 2.50Moderate Buy$7.00158.30% UpsideOLMAOlema Pharmaceuticals 2.67Moderate Buy$23.00186.43% UpsideCurrent Analyst Ratings BreakdownLatest ACOG, OLMA, CMPX, and ESPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/25/2025ESPREsperion TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/25/2025OLMAOlema PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025CMPXCompass TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/20/2025ACOGAlpha CognitionHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$20.00 ➝ $18.0010/20/2025OLMAOlema PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy10/20/2025OLMAOlema PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$28.0010/8/2025CMPXCompass TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ESPREsperion TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025OLMAOlema PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025OLMAOlema PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.0010/6/2025CMPXCompass TherapeuticsCompass PointSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$10.00(Data available from 10/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACOGAlpha CognitionN/AN/AN/AN/A$2.59 per shareN/ACMPXCompass Therapeutics$850K645.85N/AN/A$0.91 per share4.36ESPREsperion Therapeutics$332.31M1.64$0.02 per share112.79($1.97) per share-1.38OLMAOlema PharmaceuticalsN/AN/AN/AN/A$7.14 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACOGAlpha Cognition-$14.64M-$1.60N/A∞N/AN/A-80.16%-60.95%11/13/2025 (Estimated)CMPXCompass Therapeutics-$49.38M-$0.45N/AN/AN/AN/A-53.11%-46.14%11/11/2025 (Estimated)ESPREsperion Therapeutics-$51.74M-$0.49N/AN/AN/A-35.84%N/A-28.41%11/6/2025 (Estimated)OLMAOlema Pharmaceuticals-$129.47M-$1.98N/AN/AN/AN/A-42.58%-38.65%11/11/2025 (Estimated)Latest ACOG, OLMA, CMPX, and ESPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025ACOGAlpha Cognition-$0.46N/AN/AN/A$3.21 millionN/A11/11/2025Q3 2025CMPXCompass Therapeutics-$0.14N/AN/AN/AN/AN/A11/11/2025Q3 2025OLMAOlema Pharmaceuticals-$0.44N/AN/AN/AN/AN/A11/6/2025Q3 2025ESPREsperion Therapeutics$0.06N/AN/AN/A$78.33 millionN/A8/14/2025Q2 2025ACOGAlpha Cognition-$0.46-$0.65-$0.19-$0.65$2.32 million$1.66 million8/11/2025Q2 2025CMPXCompass Therapeutics-$0.13-$0.14-$0.01-$0.14N/AN/A8/11/2025Q2 2025OLMAOlema Pharmaceuticals-$0.43-$0.51-$0.08-$0.51N/AN/A8/5/2025Q2 2025ESPREsperion Therapeutics-$0.17-$0.02+$0.15-$0.02$62.55 million$82.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACOGAlpha CognitionN/AN/AN/AN/AN/ACMPXCompass TherapeuticsN/AN/AN/AN/AN/AESPREsperion TherapeuticsN/AN/AN/AN/AN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACOGAlpha CognitionN/A17.1416.83CMPXCompass TherapeuticsN/A7.667.66ESPREsperion TherapeuticsN/A1.150.76OLMAOlema Pharmaceuticals0.0111.0911.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACOGAlpha CognitionN/ACMPXCompass Therapeutics68.43%ESPREsperion Therapeutics47.39%OLMAOlema Pharmaceuticals91.78%Insider OwnershipCompanyInsider OwnershipACOGAlpha Cognition14.00%CMPXCompass Therapeutics29.80%ESPREsperion Therapeutics1.70%OLMAOlema Pharmaceuticals16.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACOGAlpha CognitionN/A20.90 million17.98 millionN/ACMPXCompass Therapeutics20138.28 million97.08 millionNot OptionableESPREsperion Therapeutics200201.62 million198.20 millionOptionableOLMAOlema Pharmaceuticals7068.63 million57.41 millionOptionableACOG, OLMA, CMPX, and ESPR HeadlinesRecent News About These CompaniesOlema Pharmaceuticals (OLMA) Gets a Buy from OppenheimerOctober 22, 2025 | theglobeandmail.comOlema Pharmaceuticals (OLMA) Gets a Buy from GuggenheimOctober 22, 2025 | theglobeandmail.comOlema Pharmaceuticals: Tapping The Brakes (Rating Downgrade)October 21, 2025 | seekingalpha.comHC Wainwright & Co. Reiterates Olema Pharmaceuticals (OLMA) Buy RecommendationOctober 21, 2025 | msn.comOlema Pharmaceuticals (NASDAQ:OLMA) Shares Up 7.3% - What's Next?October 21, 2025 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Down - Here's WhyOctober 20, 2025 | marketbeat.comOlema Shares Sink 28% as Roche Trial Results Weigh on Breast Cancer Drug OutlookOctober 20, 2025 | msn.comOlema shares drop 28% as Roche trial casts shadow on cancer dataOctober 20, 2025 | ca.investing.comOlema announces updated data on Phase 1b/2 study of palazestrant, ribociclibOctober 19, 2025 | msn.comOlema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ...October 18, 2025 | caledonianrecord.comCOlema Pharmaceuticals Reports Promising Phase 1b/2 Results of Palazestrant and Ribociclib in Advanced Breast CancerOctober 18, 2025 | quiverquant.comQOlema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025October 18, 2025 | globenewswire.comGuggenheim Initiates Olema Pharmaceuticals (OLMA) Coverage with Buy Rating and $20 PT, Cites Palazestrant PotentialOctober 16, 2025 | insidermonkey.comOlema Pharmaceuticals (NASDAQ:OLMA) Trading Up 5.7% - What's Next?October 11, 2025 | marketbeat.comWeiss Ratings Reiterates Sell (D-) Rating for Olema Pharmaceuticals (NASDAQ:OLMA)October 10, 2025 | marketbeat.comGuggenheim Initiates Coverage of Olema Pharmaceuticals (OLMA) with Buy RecommendationOctober 9, 2025 | msn.comOlema Pharmaceuticals (NASDAQ:OLMA) Earns Buy Rating from Analysts at GuggenheimOctober 8, 2025 | marketbeat.comOlema Oncology initiated with a Buy at GuggenheimOctober 8, 2025 | msn.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Average Recommendation of "Moderate Buy" from AnalystsOctober 4, 2025 | marketbeat.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2025 | globenewswire.comOlema Pharmaceuticals (NASDAQ:OLMA) Trading Down 6.3% - Time to Sell?October 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACOG, OLMA, CMPX, and ESPR Company DescriptionsAlpha Cognition NASDAQ:ACOG$6.87 -0.12 (-1.72%) As of 10/24/2025 04:00 PM EasternAlpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.Compass Therapeutics NASDAQ:CMPX$3.97 +0.08 (+2.06%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$4.08 +0.11 (+2.77%) As of 10/24/2025 05:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.Esperion Therapeutics NASDAQ:ESPR$2.71 +0.03 (+1.12%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$2.72 +0.00 (+0.18%) As of 10/24/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Olema Pharmaceuticals NASDAQ:OLMA$8.03 -0.06 (-0.74%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$7.84 -0.19 (-2.30%) As of 10/24/2025 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
